Literature DB >> 27501379

Endoscopic scoring indices for evaluation of disease activity in Crohn's disease.

Reena Khanna1, Sigrid A Nelson, Brian G Feagan, Geert D'Haens, William J Sandborn, G Y Zou, John K MacDonald, Claire E Parker, Vipul Jairath, Barrett G Levesque.   

Abstract

BACKGROUND: Endoscopic assessment of mucosal disease activity is widely used to determine eligibility and response to therapy in clinical trials of treatment for Crohn's disease. However, the operating properties of the currently available endoscopic indices remain unclear.
OBJECTIVES: A systematic review was undertaken to evaluate the development and operating characteristics of the Crohn's Disease Endoscopic Index of Severity (CDEIS) and Simple Endoscopic Scale for Crohn's Disease (SES-CD). SEARCH
METHODS: Electronic searches of the MEDLINE (1966 to December 2015), EMBASE (1980 to December 2015), and Cochrane CENTRAL Register of Controlled Trials (Issue 12, 2015) databases were supplemented by manual reviews of reference listings and conference proceedings (Digestive Disease Week, United European Gastroenterology Week, European Crohn's and Colitis Organization). SELECTION CRITERIA: Any study design (e.g. randomized controlled trials, cohort studies, case series) that evaluated either or both the CDEIS or SES-CD in patients with Crohn's disease was considered for inclusion. Eligible participants were adult patients (> 16 years), diagnosed with Crohn's disease using conventional clinical, radiographic, and endoscopic criteria. DATA COLLECTION AND ANALYSIS: Two authors (RK, JKM) independently reviewed the titles and abstracts of the studies identified from the literature search. The full texts of potentially relevant citations were reviewed for inclusion and the study investigators were contacted to clarify any unclear data. Any disagreements were resolved by discussion and consensus with a third author. A standardized form was used to assess eligibility of trials for inclusion in the study and for data extraction.Two authors independently extracted and recorded data (RK, SAN). The number of patients enrolled; number of patients per treatment arm; patient characteristics including age and gender distribution; endoscopic index; and outcomes such as intra-rater reliability, inter-rater reliability responsiveness, validity, feasibility, construct validity, and criterion validity were recorded for each trial. MAIN
RESULTS: Forty-three reports of 30 studies fulfilled the inclusion criteria.For the SES-CD, inter-rater reliability was assessed in four studies. In the development study for the SES-CD (Daperno 2004), the overall ICC (0.9815, 95% CI 0.9705 to 0.9884) and the kappa for the regions is high; however the paired raters were in the same room which introduces the potential for bias.For the CDEIS, inter-rater reliability was assessed in six studies. Daperno 2014 reported that the ICC for the CDEIS was 0.985 (95% CI 0.939-1.000) for average measures of video score and was 0.835 (95% CI 0.540-0.995) for single measures of video score.With respect to validity, correlation between the CDEIS and clinical measures, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), was also reported. The estimates of correlation with CRP were r = 0.521 (Sipponen 2010b), r = 0.553 (Sipponen 2008a) and r = 0.608 (Sipponen 2008c). For the SES-CD, the corresponding values for correlation with CRP ranged from r = 0.46 (Jones 2008) to r = 0.68 (Green 2011).Responsiveness data for the CDEIS were available in nine studies. Seven studies demonstrated statistically significant decreases in the CDEIS score after administration of a treatment of known efficacy. Minimal responsiveness data were available for the SES-CD. Sipponen 2010a and Sipponen 2010b demonstrated statistically significant changes in the SES-CD score after subjects were administered a treatment of known efficacy.No studies were identified that explicitly evaluated the feasibility for either the SES-CD or the CDEIS. The SES-CD requires fewer calculations and may therefore be easier to use than the CDEIS. AUTHORS'
CONCLUSIONS: Although they are used in clinical trials, the CDEIS and SES-CD remain incompletely validated. Future research is required to determine the operating properties and to define the optimal index.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27501379      PMCID: PMC7079710          DOI: 10.1002/14651858.CD010642.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  31 in total

1.  Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial.

Authors:  G D'haens; S Van Deventer; R Van Hogezand; D Chalmers; C Kothe; F Baert; T Braakman; T Schaible; K Geboes; P Rutgeerts
Journal:  Gastroenterology       Date:  1999-05       Impact factor: 22.682

2.  Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn's disease treatment.

Authors:  Taina Sipponen; Clas-Göran A F Björkesten; Martti Färkkilä; Hannu Nuutinen; Erkki Savilahti; Kaija-Leena Kolho
Journal:  Scand J Gastroenterol       Date:  2010-03       Impact factor: 2.423

3.  Endoscopic evaluation of Crohn's disease activity: comparison of the CDEIS and the SES-CD.

Authors:  Taina Sipponen; Hannu Nuutinen; Ulla Turunen; Martti Färkkilä
Journal:  Inflamm Bowel Dis       Date:  2010-12       Impact factor: 5.325

4.  Crohn's disease activity index does not correlate with endoscopic recurrence one year after ileocolonic resection.

Authors:  Miguel Regueiro; Kevin E Kip; Wolfgang Schraut; Leonard Baidoo; Antonia R Sepulveda; Marilyn Pesci; Sandra El-Hachem; Janet Harrison; David Binion
Journal:  Inflamm Bowel Dis       Date:  2011-01       Impact factor: 5.325

5.  Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.

Authors:  Clas-Göran af Björkesten; Urpo Nieminen; Ulla Turunen; Perttu Arkkila; Taina Sipponen; Martti Färkkilä
Journal:  Scand J Gastroenterol       Date:  2012-02-23       Impact factor: 2.423

6.  The role of centralized reading of endoscopy in a randomized controlled trial of mesalamine for ulcerative colitis.

Authors:  Brian G Feagan; William J Sandborn; Geert D'Haens; Suresh Pola; John W D McDonald; Paul Rutgeerts; Pia Munkholm; Ulrich Mittmann; Debra King; Cindy J Wong; Guangyong Zou; Allan Donner; Lisa M Shackelton; Denise Gilgen; Sigrid Nelson; Margaret K Vandervoort; Marianne Fahmy; Edward V Loftus; Remo Panaccione; Simon P Travis; Gert A Van Assche; Séverine Vermeire; Barrett G Levesque
Journal:  Gastroenterology       Date:  2013-03-22       Impact factor: 22.682

7.  Inflammatory bowel disease activity assessed by fecal calprotectin and lactoferrin: correlation with laboratory parameters, clinical, endoscopic and histological indexes.

Authors:  Andrea Vieira; Chia Bin Fang; Ernani Geraldo Rolim; Wilmar Artur Klug; Flávio Steinwurz; Lucio Giovanni Battista Rossini; Paulo Azevedo Candelária
Journal:  BMC Res Notes       Date:  2009-10-29

8.  Correlations between clinical activity, endoscopic severity, and biological parameters in colonic or ileocolonic Crohn's disease. A prospective multicentre study of 121 cases. The Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

Authors:  C Cellier; T Sahmoud; E Froguel; A Adenis; J Belaiche; J F Bretagne; C Florent; M Bouvry; J Y Mary; R Modigliani
Journal:  Gut       Date:  1994-02       Impact factor: 23.059

9.  Dynamic contrast-enhanced MRI in patients with luminal Crohn's disease.

Authors:  M L W Ziech; C Lavini; M W A Caan; C Y Nio; P C F Stokkers; S Bipat; C Y Ponsioen; A J Nederveen; J Stoker
Journal:  Eur J Radiol       Date:  2012-06-30       Impact factor: 3.528

10.  Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings.

Authors:  T Sipponen; P Kärkkäinen; E Savilahti; K-L Kolho; H Nuutinen; U Turunen; M Färkkilä
Journal:  Aliment Pharmacol Ther       Date:  2008-08-26       Impact factor: 8.171

View more
  18 in total

1.  Phenotypic Variation in Paediatric Inflammatory Bowel Disease by Age: A Multicentre Prospective Inception Cohort Study of the Canadian Children IBD Network.

Authors:  J Dhaliwal; T D Walters; D R Mack; H Q Huynh; K Jacobson; A R Otley; J Debruyn; W El-Matary; C Deslandres; M E Sherlock; J N Critch; K Bax; E Seidman; P Jantchou; A Ricciuto; M Rashid; A M Muise; E Wine; M Carroll; S Lawrence; J Van Limbergen; E I Benchimol; P Church; A M Griffiths
Journal:  J Crohns Colitis       Date:  2020-05-21       Impact factor: 9.071

Review 2.  Factors that Influence Treatment and Non-treatment Decision Making Among Individuals with Inflammatory Bowel Disease: An Integrative Review.

Authors:  Kendra J Kamp; Kelly Brittain
Journal:  Patient       Date:  2018-06       Impact factor: 3.883

Review 3.  Inflammatory bowel disease (IBD) position statement of the Italian Society of Colorectal Surgery (SICCR): general principles of IBD management.

Authors:  G Pellino; D S Keller; G M Sampietro; V Annese; M Carvello; V Celentano; C Coco; F Colombo; N Cracco; F Di Candido; M Franceschi; S Laureti; G Mattioli; L Pio; G Sciaudone; G Sica; V Villanacci; R Zinicola; S Leone; S Danese; A Spinelli; G Delaini; F Selvaggi
Journal:  Tech Coloproctol       Date:  2020-01-25       Impact factor: 3.781

Review 4.  Evolution of Clinical Trials in Inflammatory Bowel Diseases.

Authors:  Siddharth Singh
Journal:  Curr Gastroenterol Rep       Date:  2018-08-04

5.  Editorial: Endoscopic Scoring Systems in Crohn's Disease for Evaluation of Responsiveness to Treatment: Are we Ready for the Prime Time of Endoscopic Assessment?

Authors:  Anna M Buchner; Gary R Lichtenstein
Journal:  Am J Gastroenterol       Date:  2017-10       Impact factor: 10.864

6.  The Phenotypic Spectrum of New-onset IBD in Canadian Children of South Asian Ethnicity: A Prospective Multi-Centre Comparative Study.

Authors:  J Dhaliwal; M W Carroll; J C deBruyn; A Ricciuto; E I Benchimol; S Lawrence; M Sherlock; W El-Matary; H Brill; P Church; E Wine; N Carman; A Muise; H Huynh; D R Mack; T D Walters; A M Griffiths; K Jacobson
Journal:  J Crohns Colitis       Date:  2022-02-23       Impact factor: 10.020

7.  Recruitment of activated neutrophils correlates with disease severity in adult Crohn's disease.

Authors:  A Therrien; L Chapuy; M Bsat; M Rubio; G Bernard; E Arslanian; K Orlicka; A Weber; B-P Panzini; J Dorais; E-J Bernard; G Soucy; M Bouin; M Sarfati
Journal:  Clin Exp Immunol       Date:  2018-11-28       Impact factor: 4.330

8.  Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease.

Authors:  Remo Panaccione; A Hillary Steinhart; Brian Bressler; Reena Khanna; John K Marshall; Laura Targownik; Waqqas Afif; Alain Bitton; Mark Borgaonkar; Usha Chauhan; Brendan Halloran; Jennifer Jones; Erin Kennedy; Grigorios I Leontiadis; Edward V Loftus; Jonathan Meddings; Paul Moayyedi; Sanjay Murthy; Sophie Plamondon; Greg Rosenfeld; David Schwartz; Cynthia H Seow; Chadwick Williams; Charles N Bernstein
Journal:  J Can Assoc Gastroenterol       Date:  2018-07-10

9.  Can serum histone H4 levels predict mucosal healing in Crohn's disease?

Authors:  Ibrahim Hakki Köker; Bilge Sumbul Gultepe; Sercan Kiremitçi; Koray Koçhan; Ali Tuzun Ince; Elmas Biberci Keskin; Hakan Senturk
Journal:  Prz Gastroenterol       Date:  2021-06-04

Review 10.  A review of hematopoietic stem cell transplantation for autoimmune diseases: multiple sclerosis, systemic sclerosis and Crohn's disease. Position paper of the Brazilian Society of Bone Marrow Transplantation.

Authors:  Maria Carolina Oliveira; Juliana Bernardes Elias; Daniela Aparecida de Moraes; Belinda Pinto Simões; Morgani Rodrigues; Andreza Alice Feitosa Ribeiro; Lilian Piron-Ruiz; Milton Arthur Ruiz; Nelson Hamerschlak
Journal:  Hematol Transfus Cell Ther       Date:  2020-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.